Medication adherence and relapse in patients with schizophrenia: A literature review
DOI: https://doi.org/10.56922/mhc.v5i1.2736
Medication Adherence Relapse Schizophrenia
Abstract
Background: Schizophrenia is a chronic psychiatric disorder with high relapse rates that significantly affect social functioning, quality of life, and healthcare burden. Medication adherence to antipsychotic treatment plays a critical role in maintaining clinical stability and preventing relapse; however, it remains a major challenge in clinical practice.
Purpose: To examine the relationship between medication adherence and relapse among patients with schizophrenia through a narrative review approach.
Method: Literature searches were conducted in Google Scholar, PubMed, NCBI, ScienceDirect, and Elsevier between January and February 2024 using keywords related to medication adherence, schizophrenia, and relapse. Of the 85 identified articles, 8 studies met the inclusion criteria and were analyzed narratively.
Results: The review findings consistently demonstrated that non-adherence to antipsychotic medication was associated with a significantly higher risk of relapse, rehospitalization, and poorer long-term prognosis. Additionally, considerable variability was observed in the definitions and assessment methods of adherence and relapse across studies.
Conclusion: Medication adherence is a key determinant in relapse prevention among patients with schizophrenia and should be a primary focus of long-term clinical management.
Keywords: Medication Adherence; Relapse; Schizophrenia.
Downloads
References
Alhadidi, M., Abdullah, K. L., Tang, L. Y., Danaee, M., & Al Hadid, L. A. R. (2021). Knowledge about schizophrenia, insight into illness, and internalized stigma and their associated factors among people diagnosed with schizophrenia in a long‐term care facility. Perspectives in psychiatric care, 57(1).
An, Y., Fang, G., Pi, Z., Zhang, Y., Li, W., & Ding, J. (2025). Cost-utility of aripiprazole once-monthly versus paliperidone palmitate once-monthly injectable for schizophrenia in China. Plos one, 20(6), e0317393.
Anwar, A., Mustafa, A. M., Abdou, K., A. Rabie, M., El-Shiekh, R. A., & El-Dessouki, A. M. (2025). A comprehensive review on schizophrenia: epidemiology, pathogenesis, diagnosis, conventional treatments, and proposed natural compounds used for management. Naunyn-Schmiedeberg's Archives of Pharmacology, 1-25.
Balikai, S. I., Rentala, S., Mudakavi, I. B., & Nayak, R. B. (2022). Impact of nurse‐led medication adherence therapy on bipolar affective disorder: A randomized controlled trial. Perspectives in Psychiatric Care, 58(4), 2676-2686.
Brasso, C., Cisotto, M., Ghirardini, C., Pennazio, F., Villari, V., & Rocca, P. (2021). Accuracy of self-reported adherence and therapeutic drug monitoring in a psychiatric emergency ward. Psychiatry Research, 305, 114214.
Chatterjee, I., & Chatterjee, S. (2023). Investigating the symptomatic and morphological changes in the brain based on pre and post-treatment: A critical review from clinical to neuroimaging studies on schizophrenia. IBRO Neuroscience Reports, 14, 366-374.
Cooter, A., Saluja, S., Roberts, S., & Branjerdporn, G. (2025). Pharmacotherapy profile for mothers with schizophrenia and bipolar affective disorder in a psychiatric mother–baby unit. Journal of Pharmacy Practice and Research, 55(1), 36-45.
Cristarella, T., Castillon, G., Nepveu, J. F., & Moride, Y. (2022). Impact of schizophrenia relapse definition on the comparative effectiveness of oral versus injectable antipsychotics: A systematic review and meta‐analysis of observational studies. Pharmacology Research & Perspectives, 10(1), e00915.
Day, M. A., Ehde, D. M., Burns, J., Ward, L. C., Friedly, J. L., Thorn, B. E., & Jensen, M. P. (2020). A randomized trial to examine the mechanisms of cognitive, behavioral and mindfulness-based psychosocial treatments for chronic pain: study protocol. Contemporary Clinical Trials, 93, 106000.
Díaz-Fernández, S., López-Muñoz, F., & Fernández-Miranda, J. J. (2021). Psychosocial and pharmacological approaches for improving treatment adherence and outcomes in people with severe schizophrenia: a 10-year follow-up. Journal of Psychiatric Practice®, 27(6), 417-426.
Faizi, A., & Stahl, S. M. (2025). Medications for psychosis in people with schizophrenia: what happens if you take them and what happens if you don’t?. CNS spectrums, 30(1), e81.
Farisa, A., Dineva, F., & Novitayani, S. (2024). Korelasi Antara Kepatuhan Minum Obat Dan Kualitas Hidup Pada Pasien Skizofrenia Rawat Jalan. Indonesian Journal of Professional Nursing, 5(1), 55-62.
Fitri, A., & Rahmandani, A. (2020). Pengalaman Keterlibatan Ayah Dalam Merawat Anak Dengan Skizofrenia: Interpretative Phenomenological Analysis. Jurnal Empati, 9(3), 204-211.
Horikoshi, S., Miura, I., Mui, A., Hikichi, T., Aono, T., Hoshino, K. Y., & Yabe, H. (2022). Second-Generation Antipsychotic Long-Acting Injection Reduced the Time of Restrictive Interventions in Patients With Schizophrenia: Retrospective, A 4-Year Mirror-Image Study. Journal of Clinical Psychopharmacology, 42(6), 526-529.
Indriani, C., Idrus, M., & Saputri, A. (2024). Faktor-Faktor Yang Berhubungan Dengan Penatalaksanaan Patuh Minum Obat Pasien Skizofrenia Di Rumah Sakit Jiwa Kota Kendari. Jurnal Anoa Keperawatan Mandala Waluya, 3(1), 26-34.
Li, X., Xiao, S., Sun, Y., Zheng, Y., Huang, J., Wei, N., & Teng, Y. (2025). Medication adherence and needs among patients with schizophrenia in China: a qualitative study. BMJ open, 15(1), e092073.
Liang, X., Hu, X., Zhang, X., & Fu, H. (2020). ASF (a Compound of Traditional Chinese Medicine) in the treatment of patients with alcohol dependence: Study protocol of a randomized, double-blinded, placebo-controlled clinical trial. Medicine, 99(52), e23899.
Luo, X., Liu, F., Lu, J., Cheng, Y., Xu, X., He, X., & Wang, J. (2024). Health economics study of paliperidone palmitate in the treatment of schizophrenia: a 12-month cohort study. BMC psychiatry, 24(1), 439.
Mlay, J. P., Naidu, T., Ramlall, S., Mhlungu, S. S., Zondi, M., Lessells, R., & Tomita, A. (2024). Risk factors and strategies for relapse prevention among individuals living with serious mental illness in South Africa: Qualitative inquiry from patients’ and caregivers’ perspectives. PLoS One, 19(8), e0309238.
Mlay, J. P., Naidu, T., Ramlall, S., Patankar, K., Israel, K., Esquivel, L., & Manuel, J. I. (2025). Strategies for relapse prevention among people with schizophrenia in KwaZulu-Natal Province, South Africa: Healthcare providers’ perspectives. Plos one, 20(3), e0316313.
Pandey, S., Pitakpatapee, Y., Saengphatrachai, W., Chouksey, A., Tripathi, M., & Srivanitchapoom, P. (2023). Drug-induced movement disorders. In Seminars in Neurology (Vol. 43, No. 01, pp. 035-047). Thieme Medical Publishers, Inc.
Paton, C., Okocha, C. I., & Patel, M. X. (2022). Can the use of long-acting injectable antipsychotic preparations be increased in routine clinical practice and the benefits realised?. Therapeutic Advances in Psychopharmacology, 12, 20451253211072347.
Potkin, S. G., Kane, J. M., Correll, C. U., Lindenmayer, J. P., Agid, O., Marder, S. R., & Howes, O. D. (2020). The neurobiology of treatment-resistant schizophrenia: paths to antipsychotic resistance and a roadmap for future research. NPJ schizophrenia, 6(1), 1.
Ran, M. S., Wang, Y. Z., Lu, P. Y., Weng, X., Zhang, T. M., Deng, S. Y., & Lu, L. (2022). Effectiveness of enhancing contact model on reducing stigma of mental illness among family caregivers of persons with schizophrenia in rural China: A cluster randomized controlled trial. The Lancet Regional Health–Western Pacific, 22.
Restelli, U., García-Goñi, M., Lew-Starowicz, M., Mierzejewski, P., Silvola, S., Mayoral-van Son, J., & Crespo-Facorro, B. (2020). Cost of relapse management in patients with schizophrenia in Italy and Spain: comparison between lurasidone and quetiapine XR. Clinical drug investigation, 40(9), 861-871.
Rubio, J. M., & Kane, J. M. (2022). The pharmacological treatment of schizophrenia: How far have we come?. Psychiatry and Clinical Neurosciences Reports, 1(2), e13.
Sharif, N. V., Ghasemzadeh, P., Mohebbi, N., & Ghasemzadeh, S. (2025). Improved medication adherence and health literacy in parents of children with ADHD: Effects of a targeted educational program. Exploratory Research in Clinical and Social Pharmacy, 100634.
Smithnaraseth, A., Seeherunwong, A., Panitrat, R., & Tipayamongkholgul, M. (2020). Hospital and patient factors influencing the health status among patients with schizophrenia, thirty days after hospital discharge: multi-level analysis. BMC psychiatry, 20(1), 592.
Sriboonruang, T., Phonphairin, W., Phattanarudee, S., & Chusiri, S. (2024). Effectiveness of pharmaceutical care for improving medication‐related quality of life and adherence to treatment among people living with schizophrenia: a randomised controlled trial. Journal of Pharmacy Practice and Research, 54(3), 217-227.
Suliyanti, N. W., Adianta, I. K. A., & Negara, I. G. N. M. K. (2021). Hubungan Dukungan Keluarga dengan Kepatuhan Kunjungan Kontrol Rawat Jalan pada Pasien Skizofrenia. Jurnal Riset Kesehatan Nasional, 5(1), 59-65.
Vázquez Morejón, A. J., León Rubio, J. M., & Vázquez-Morejón, R. (2023). Sources of social support and clinical and functional evolution of people with schizophrenia. International Journal of Social Psychiatry, 69(6), 1377-1387.
Wu, T., Xiao, X., Yan, S., Fang, Y., Wang, M., Zu, F., & Qian, R. (2023). Digital health interventions to improve adherence to oral antipsychotics among patients with schizophrenia: a scoping review. BMJ open, 13(11), e071984.
Yousuf, S. M., Eldous, A. Z. K., Ikhlef, F. W., Chandrappa, N. S. K., & Abdulla, M. A. Y. A. (2025). Low‐Dose Clozapine Reduces Aggression in Violent Substance Use Disorder Patients at a Secure Rehabilitation Center. Case Reports in Psychiatry, 2025(1), 9578923.
Zygmunt, A., Olfson, M., Boyer, C. A., & Mechanic, D. (2022). Interventions to improve medication adherence in schizophrenia. American journal of Psychiatry, 159(10), 1653-1664.
Downloads
Published
Issue
Section
License
Copyright (c) 2026 JOURNAL OF Mental Health Concerns
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
